Blood viscosity, finger systolic pressure and effect of dazoxiben treatment in primary vasospastic disease.
Whole blood viscosity, plasma viscosity, erythrocyte deformability, and finger systolic pressure (FSP) were measured in ten patients with primary vasospastic (Raynaud's) disease before and after a controlled double-blind prospective trial involving dazoxiben (a thromboxane inhibitor, Pfizer). Five of the patients were assigned to dazoxiben and five to placebo. Before treatment, the FSP at 10 degrees C in the patient groups was significantly lower than that in a normal reference group, but all rheologic variables, measured at 37 and 10 degrees C, were normal. There was no significant correlation between FSP and rheology. Dazoxiben did not yield any subjective relief or give any objective effect.
D000328:Adult; D001809:Blood Viscosity / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005385:Fingers / Q000098:blood supply; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D011446:Prospective Studies; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D013599:Systole / Q000187:drug effects*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D007093:Imidazoles; C029166:dazoxiben; D013930:Thromboxane-A Synthase